Vcanbio Cell & Gene Engineering (600645.SS) Earnings Analysis

Vcanbio Cell & Gene Engineering (600645.SS) has no confirmed upcoming earnings date. Trailing P/E 78.84.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 600645.SS next report earnings?

No confirmed upcoming earnings date is currently scheduled for 600645.SS. This page updates as the calendar is published.

600645.SS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-250.0126 CNYn/an/an/a
2025-09-290.11 CNYn/an/an/a
2025-08-270.06366 CNYn/an/an/a
2025-04-24-0.07183 CNYn/an/an/a
2025-03-310.06 CNYn/an/an/a
2024-08-290.09 CNYn/an/an/a

600645.SS valuation and analyst view

Trailing P/E78.84
Trailing EPS0.22695 CNY
Price / book2.43
Dividend yield0.00%
Market cap8.41B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Vcanbio Cell & Gene Engineering (600645.SS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 600645.SS. This page updates as the calendar is published.

Did 600645.SS beat earnings last quarter?

Consensus estimate data was not available for 600645.SS's 2026-04-25 report.

What is 600645.SS's current P/E ratio and EPS?

600645.SS trades at a trailing P/E of 78.84 on trailing EPS of 0.22694589290404588 CNY.

What do analysts rate 600645.SS?

600645.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.